IOBT - IO Biotech, Inc. Stock Price, Fair Value and News

$0.77+0.01 (+1.32%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IOBT Price Action

Last 7 days

-4.9%

Last 30 days

-6.1%

Last 90 days

-31.9%

Trailing 12 Months

-47.3%

IOBT RSI Chart

IOBT Valuation

Market Cap

50.7M

Price/Earnings (Trailing)

-0.56

Price/Sales (Trailing)

8.53

EV/EBITDA

0.33

Price/Free Cashflow

-0.59

IOBT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IOBT Fundamentals

IOBT Revenue

Revenue (TTM)

5.9M

Rev. Growth (Yr)

-37.47%

Rev. Growth (Qtr)

-18.54%

IOBT Earnings

Earnings (TTM)

-90.4M

Earnings Growth (Yr)

-10.78%

Earnings Growth (Qtr)

-16.09%

IOBT Profitability

EBT Margin

-1496.87%

Return on Equity

-124.52%

Return on Assets

-100.46%

Free Cashflow Yield

-168.86%

IOBT Investor Care

Diluted EPS (TTM)

-1.24

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.5M	6.6M	5.9M	0
2023	2.4M	3.5M	4.7M	5.9M
2022	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

CEO	Dr. Mai-Britt Zocca Ph.D.
WEBSITE	iobiotech.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	57

IO Biotech, Inc. Frequently Asked Questions

What is the ticker symbol for IO Biotech, Inc.? What does IOBT stand for in stocks?

IOBT is the stock ticker symbol of IO Biotech, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of IO Biotech, Inc. (IOBT)?

As of Fri Dec 20 2024, market cap of IO Biotech, Inc. is 50.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IOBT stock?

You can check IOBT's fair value in chart for subscribers.

Is IO Biotech, Inc. a good stock to buy?

The fair value guage provides a quick view whether IOBT is over valued or under valued. Whether IO Biotech, Inc. is cheap or expensive depends on the assumptions which impact IO Biotech, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IOBT.

What is IO Biotech, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, IOBT's PE ratio (Price to Earnings) is -0.56 and Price to Sales (PS) ratio is 8.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IOBT PE ratio will change depending on the future growth rate expectations of investors.